Buy Stivarga (Regorafenib) Online

The active ingredient in Stivarga is regorafenib.

Stivarga works as a targeted cancer therapy that blocks multiple protein kinases involved in tumour growth and blood vessel formation. By inhibiting these kinases, it slows cancer cell growth and cuts off the blood supply tumours need to survive. This helps limit tumour progression and is why Stivarga is used in certain advanced cancers such as colorectal cancer and gastrointestinal stromal tumours.

Follow all directions given to you by your doctor and read all documents provided, including the full Prescribing Information, FDA-Approved Product Labelling, Instructions for Use, and Medication Guide before using Stivarga. However, the following is a synopsis of the general guidelines for the use of Stivarga:

• Stivarga is taken by mouth once daily.
• It is usually taken for 21 days in a row, followed by 7 days off, which completes one treatment cycle.
• Tablets should be taken after a low-fat meal.
• Tablets should be swallowed whole with water and not crushed or chewed.
• Your healthcare provider may adjust the dose of Stivarga based on side effects or lab results.
• Regular blood tests, including liver function tests, are required during treatment.
• Treatment continues as long as the medication is effective and side effects are manageable.

If you miss a dose, take it as soon as you remember on the same day. Do not take an extra dose the next day to make up for a missed dose.

Some mild or most common side effects of regorafenib seen in clinical trials as compared to placebo include:

• Tiredness or weakness.
• Decreased appetite or loss of appetite.
• Weight loss.
• Diarrhea.
• Lightheadedness.
• Shortness of breath.
• Mucositis or mouth sores.
• Hoarseness, sore throat or dysphonia.
• Skin rash or other skin problems.
• Hand-foot skin reaction with redness, pain, or blisters.
• Nose bleeds.
• Severe rash.

Some individuals may experience serious side effects while using Stivarga. These side effects may require immediate medical attention. If you experience any of the following, contact your healthcare provider or seek emergency medical help:

• Liver problems, including yellowing of the skin or eyes, dark urine, or abnormal liver function tests.
• Severe bleeding, including vomiting blood or coffee-ground-like material, or black stools.
• High blood pressure that is difficult to control.
• Heart problems, including chest pain or a heart attack.
• Blood clots.
• Gastrointestinal perforation or fistula.
• Reversible posterior leukoencephalopathy syndrome with symptoms such as severe headache, seizures, confusion, or vision changes.
• Severe skin reactions.

These are not all of the possible side effects of Stivarga. You should always seek medical advice from your healthcare provider for any questions or concerns about your medical condition or treatment. Read all patient information, medication guides, or drug information sheets that come with this medication. You can also report adverse effects to the Food and Drug Administration at www.fda.gov/medwatch or 1-800-FDA-1088.

Before starting Stivarga, it is crucial to discuss any existing health conditions with your healthcare provider. You should be sure that your healthcare provider is aware of all your medical conditions, including:

• Liver disease or abnormal liver function tests.
• High blood pressure or heart problems.
• A history of bleeding problems.
• Wound healing issues or recent surgery.
• Kidney disease.
• A history of stroke or blood clots.
• Close monitoring is required during treatment to reduce the risk of serious toxicity.

Boxed Warning

Stivarga has a boxed warning for liver toxicity. Severe and sometimes fatal liver problems have occurred in patients treated with Stivarga. Liver function tests must be performed before starting treatment and monitored regularly during therapy. Treatment should be interrupted, reduced, or permanently discontinued depending on the severity of liver injury.

There are no absolute contraindications listed for Stivarga. However, it should not be used in patients with severe hypersensitivity to regorafenib or any component of the formulation.

Stivarga begins working after treatment starts, but it may take several weeks or months to see a measurable effect. In clinical trials, benefit was assessed using progression-free survival and overall survival. Your healthcare provider will monitor treatment response through imaging, blood tests, and symptom changes.

When Stivarga is taken with other prescription drugs, over-the-counter medications, vitamins, and supplements, it may change how they work or increase the frequency or severity of side effects. Make sure that you tell your healthcare professional about anything that you are taking to avoid any negative drug interactions, including:

• Ketoconazole may increase regorafenib levels and toxicity.
• St. John’s wort may reduce the effectiveness by lowering drug levels.
• Grapefruit juice may increase drug exposure.
• Other kinase inhibitors, such as sorafenib or sunitinib, may increase side effects.

Stivarga is available as oral tablets. The standard dose is determined by the prescribing healthcare provider and may be adjusted based on tolerance and side effects.

It should be stored at room temperature, away from the reach of children or pets.

Stivarga is manufactured by Bayer HealthCare.

No. There is currently no generic version of Stivarga available.

Do not stop taking Stivarga without talking to your healthcare provider. Treatment may be paused or stopped if serious side effects occur or if the medication is no longer effective.

Talk to your doctor if you are already pregnant or if you have any plans to become pregnant. Stivarga can cause harm to an unborn baby. Effective contraception should be used during treatment and for a period after the last dose.

Talk to your doctor if you are already breastfeeding or if you have any plans to breastfeed. Breastfeeding is not recommended during treatment with Stivarga and for at least two weeks after the final dose.